MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Amicus Therapeutics Inc

Fermé

SecteurSoins de santé

8 0.76

Résumé

Variation du prix de l'action

24h

Actuel

Min

7.84

Max

8.01

Chiffres clés

By Trading Economics

Revenu

21M

15M

Ventes

8.2M

150M

BPA

0.09

Marge bénéficiaire

9.845

Employés

499

EBITDA

286K

22M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+104.03% upside

Dividendes

By Dow Jones

Prochains Résultats

8 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-263M

2.6B

Ouverture précédente

7.24

Clôture précédente

8

Sentiment de l'Actualité

By Acuity

7%

93%

3 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Amicus Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 avr. 2025, 23:55 UTC

Actions en Tendance

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 avr. 2025, 22:50 UTC

Principaux Mouvements du Marché

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 avr. 2025, 21:08 UTC

Résultats

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 avr. 2025, 21:00 UTC

Résultats

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 avr. 2025, 23:56 UTC

Market Talk

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 avr. 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

2 avr. 2025, 23:44 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 avr. 2025, 23:44 UTC

Actualités

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 avr. 2025, 23:32 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 avr. 2025, 23:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 avr. 2025, 23:32 UTC

Market Talk

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 avr. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

2 avr. 2025, 23:12 UTC

Market Talk

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 avr. 2025, 23:10 UTC

Market Talk

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 avr. 2025, 23:09 UTC

Market Talk

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 avr. 2025, 23:09 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 avr. 2025, 22:57 UTC

Market Talk

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 avr. 2025, 22:56 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 avr. 2025, 22:56 UTC

Market Talk

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 avr. 2025, 22:43 UTC

Actualités
Acquisitions, Fusions, Rachats

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 avr. 2025, 22:12 UTC

Market Talk

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 avr. 2025, 21:48 UTC

Actualités

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 avr. 2025, 21:41 UTC

Market Talk

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 avr. 2025, 21:17 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 avr. 2025, 21:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 avr. 2025, 21:17 UTC

Market Talk

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 avr. 2025, 21:04 UTC

Actualités

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 avr. 2025, 21:03 UTC

Market Talk

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 avr. 2025, 20:53 UTC

Résultats

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 avr. 2025, 20:52 UTC

Résultats

Kaiser Aluminum Changes Inventory Acctg Methodology

Comparaison

Variation de prix

Amicus Therapeutics Inc prévision

Objectif de Prix

By TipRanks

104.03% hausse

Prévisions sur 12 Mois

Moyen 16.22 USD  104.03%

Haut 21 USD

Bas 12 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

10 ratings

7

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

7.9 / 8.63Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

3 / 386Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.